Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, and Lisata Therapeutics, Inc. (LSTA) recently announced a research collaboration for using the Haystack MRD (minimal residual disease) technology. Under the partnership, Lisata will deploy the highly sensitive technology to detect the circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer. DGX completed the validation of the Haystack MRD test in March 2 ...